Kuuleikuponookealoha Naahielua, APRN
Psychiatric/Mental Health · Aiea, HINPI 1467826925
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 372 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 25.2% of the total. 2025 is the largest year on record at $3,745, 2.8 times the $1,316 reported in 2021. Among psychiatric/mental health clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 372 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$1K
- Mannkind Corporation$705
- Otsuka America Pharmaceutical, Inc.$484
- Alkermes, Inc.$291
- plus $2K from 15 others
What the payments were for
- Food & beverage$8,03396%
- Education$3334%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 118 | $2,109 |
| Teva Pharmaceuticals USA, Inc. | 48 | $1,258 |
| AbbVie | 41 | $1,257 |
| Mannkind Corporation | 29 | $705 |
| Otsuka America Pharmaceutical, Inc. | 23 | $484 |
| Alkermes, Inc. | 17 | $291 |
| Insulet Corporation | 13 | $280 |
| Johnson & Johnson | 9 | $272 |
| E.r. Squibb & Sons, L.L.C. | 11 | $259 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $248 |
| AstraZeneca | 10 | $203 |
| Bayer | 10 | $201 |
| Xeris Pharmaceuticals, Inc. | 9 | $187 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $133 |
| Dexcom, Inc. | 4 | $100 |
| Boehringer Ingelheim | 4 | $99 |
| Lilly USA, LLC | 5 | $92 |
| Abbott | 4 | $78 |
| Corcept Therapeutics | 3 | $61 |
| Lundbeck LLC | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$375
- Austedo XR$250
- ABILIFY ASIMTUFII$133
- REXULTI$133
- AFREZZA$113
How this compares
$8,366 in reported general payments places this provider in the 95th percentile of 103 psychiatric/mental health providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $156,090 |
| Invega SustennaPaliperidone Palmitate | 45 | $136,767 |
| Austedo XrDeutetrabenazine | 16 | $117,059 |
| VraylarCariprazine Hcl | 86 | $110,148 |
| Abilify MaintenaAripiprazole | 22 | $61,662 |
| FarxigaDapagliflozin Propanediol | 31 | $48,387 |
| MounjaroTirzepatide | 25 | $41,456 |
| RybelsusSemaglutide | 20 | $30,150 |
| KerendiaFinerenone | 17 | $26,544 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $22,078 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $19,695 |
| AristadaAripiprazole Lauroxil | 12 | $18,236 |
| Novolog FlexpenInsulin Aspart | 15 | $4,589 |
| Aripiprazole | 27 | $4,028 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $3,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,109 | $186,24099 claims |
| Johnson & JohnsonInvega Sustenna | $272 | $136,76745 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,258 | $117,05916 claims |
| AbbVieVraylar | $1,257 | $110,14886 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $484 | $61,66222 claims |
| AstraZenecaFarxiga | $203 | $48,38731 claims |
| Lilly USA, LLCMounjaro | $92 | $41,45625 claims |
| BayerKerendia | $201 | $26,54417 claims |
| Alkermes, Inc.Aristada | $291 | $18,23612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 103 psychiatric/mental health providers in Hawaii.
Other psychiatric/mental health in Aiea
- Jeremy CreekmoreAiea$13K
- Tracy IngramAiea$635
- J D BrandmanHonolulu$63K
- Melissa GarnettHilo$6K
- Jacqueline WernerKapolei$6K
- Dave FieldsMililani$6K
- David GuoHonolulu$5K
- Tammy WheelerHilo$5K
- Angela BroganKahului$4K
- Christopher AtenHonolulu$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.